Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for setmelanotide as a treatment for acquired hypothalamic obesity. Setmelanotide is a melanocortin-4 receptor agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic obesity, with topline data on track to be disclosed in the second quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Buy Rating for Rhythm Pharmaceuticals: Setmelanotide’s Potential in Addressing Unmet Needs in Hypothalamic Obesity
- Rhythm Pharmaceuticals: Buy Rating on Promising Setmelanotide Phase 3 Data for Hypothalamic Obesity
- Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
- Rhythm Pharmaceuticals price target raised to $66 from $64 at Needham
- Rhythm Pharmaceuticals, Raymond A. Wood Fountain announce research collab